{"analyses":[{"ciLowerLimit":"3.800","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.191","groupDescription":"Odds ratio: CZP/Placebo and p-value were calculated using logistic regression with factors for treatment, region and MRI/CRP classification.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"6.223","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"115"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"The number of subjects who did not have relevant changes to background medications during the study treatment period.\n\nA subject is without relevant changes to background medication if they do not have: the addition of a new disease-modifying antirheumatic drug (DMARD) or the change from one DMAR to another; the addition of an nonsteroidal anti-inflammatory drug (NSAID) or the change from one NSAID to another; an increased dose of chronic corticosteroids; the addition of a new chronic analgesic medication or increased dose in chronic analgesic medication; and they complete double-blind study treatment to Week 52.","groups":[{"description":"Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards. Subjects formed the Full Analysis Set (FAS).","id":"OG000","title":"Placebo (FAS)"},{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the FAS.","id":"OG001","title":"CZP 200 mg Q2W (FAS)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS consisted of all subjects in the RS who have received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"From Baseline to Week 52","title":"Number of Subjects Without Relevant Changes to Background Medication From Baseline to Week 52","type":"SECONDARY","unitOfMeasure":"Participants"}